Ikena Oncology (IKNA) Competitors $1.72 +0.01 (+0.58%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends IKNA vs. XLO, VOR, IVA, BMEA, CMPS, ITOS, JSPR, TSHA, RZLT, and PRQRShould you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include Xilio Therapeutics (XLO), Vor Biopharma (VOR), Inventiva (IVA), Biomea Fusion (BMEA), COMPASS Pathways (CMPS), iTeos Therapeutics (ITOS), Jasper Therapeutics (JSPR), Taysha Gene Therapies (TSHA), Rezolute (RZLT), and ProQR Therapeutics (PRQR). These companies are all part of the "medical" sector. Ikena Oncology vs. Xilio Therapeutics Vor Biopharma Inventiva Biomea Fusion COMPASS Pathways iTeos Therapeutics Jasper Therapeutics Taysha Gene Therapies Rezolute ProQR Therapeutics Ikena Oncology (NASDAQ:IKNA) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment. Do insiders and institutionals hold more shares of IKNA or XLO? 75.0% of Ikena Oncology shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 5.9% of Ikena Oncology shares are held by company insiders. Comparatively, 5.2% of Xilio Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is IKNA or XLO more profitable? Ikena Oncology's return on equity of -40.71% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ikena OncologyN/A -40.71% -34.40% Xilio Therapeutics N/A -173.95%-83.00% Do analysts prefer IKNA or XLO? Ikena Oncology currently has a consensus target price of $3.00, indicating a potential upside of 74.42%. Given Ikena Oncology's higher possible upside, equities research analysts plainly believe Ikena Oncology is more favorable than Xilio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ikena Oncology 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Which has more volatility & risk, IKNA or XLO? Ikena Oncology has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Does the MarketBeat Community favor IKNA or XLO? Ikena Oncology received 18 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Xilio Therapeutics an outperform vote while only 60.42% of users gave Ikena Oncology an outperform vote. CompanyUnderperformOutperformIkena OncologyOutperform Votes2960.42% Underperform Votes1939.58% Xilio TherapeuticsOutperform Votes1173.33% Underperform Votes426.67% Which has preferable valuation and earnings, IKNA or XLO? Ikena Oncology has higher revenue and earnings than Xilio Therapeutics. Ikena Oncology is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIkena Oncology$9.16M9.06-$68.17M-$1.42-1.21Xilio TherapeuticsN/AN/A-$76.40M-$2.11-0.63 Does the media favor IKNA or XLO? In the previous week, Xilio Therapeutics had 2 more articles in the media than Ikena Oncology. MarketBeat recorded 2 mentions for Xilio Therapeutics and 0 mentions for Ikena Oncology. Ikena Oncology's average media sentiment score of 1.00 beat Xilio Therapeutics' score of 0.50 indicating that Ikena Oncology is being referred to more favorably in the media. Company Overall Sentiment Ikena Oncology Positive Xilio Therapeutics Neutral SummaryIkena Oncology beats Xilio Therapeutics on 12 of the 15 factors compared between the two stocks. Ad Opportunistic TraderMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicted the 2020 crash a month before it happened...For a limited time, he's revealing his latest forecast here. Get Ikena Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IKNA vs. The Competition Export to ExcelMetricIkena OncologyBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$83.01M$3.14B$5.33B$8.52BDividend YieldN/A1.77%5.07%4.13%P/E Ratio-1.2116.37128.5716.13Price / Sales9.06318.331,489.0093.67Price / CashN/A149.0539.6234.18Price / Book0.494.024.765.07Net Income-$68.17M-$42.25M$118.92M$225.46M7 Day PerformanceN/A8.04%0.79%0.54%1 Month Performance2.38%8.69%5.63%3.75%1 Year Performance-57.64%32.09%36.69%29.48% Ikena Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IKNAIkena Oncology3.0935 of 5 stars$1.72+0.6%$3.00+74.4%-57.7%$83.01M$9.16M-1.2170XLOXilio Therapeutics1.8149 of 5 stars$1.32+3.9%N/A-42.7%$58.01MN/A-0.6373News CoverageVORVor Biopharma1.68 of 5 stars$0.80-4.7%$10.92+1,256.4%-51.4%$55.05MN/A-0.46140Upcoming EarningsNews CoverageIVAInventiva2.7425 of 5 stars$2.75+3.4%$17.67+542.4%-26.5%$144.32M$18.91M0.00100Gap DownBMEABiomea Fusion3.8084 of 5 stars$9.04-3.5%$30.50+237.4%-13.5%$327.61MN/A-2.2550Earnings ReportAnalyst ForecastAnalyst RevisionCMPSCOMPASS Pathways2.2856 of 5 stars$4.75-0.2%$30.67+545.6%-17.8%$324.85MN/A-2.06120Analyst ForecastShort Interest ↓News CoverageHigh Trading VolumeITOSiTeos Therapeutics3.0375 of 5 stars$8.81+4.3%$30.50+246.2%-11.1%$321.74M$12.60M-2.9490Upcoming EarningsJSPRJasper Therapeutics3.4255 of 5 stars$21.27+0.4%$74.86+251.9%+210.4%$321.18MN/A-4.1720TSHATaysha Gene Therapies1.6547 of 5 stars$1.53-9.5%$6.38+316.7%-35.8%$313.56M$15.45M-7.65180News CoverageHigh Trading VolumeRZLTRezolute3.7018 of 5 stars$5.50+0.4%$11.57+110.4%+436.6%$307.62MN/A-4.1440News CoveragePRQRProQR Therapeutics2.8802 of 5 stars$3.73+6.6%$5.88+57.5%+221.6%$304.67M$7.05M-12.86180Upcoming EarningsAnalyst Upgrade Related Companies and Tools Related Companies XLO Competitors VOR Competitors IVA Competitors BMEA Competitors CMPS Competitors ITOS Competitors JSPR Competitors TSHA Competitors RZLT Competitors PRQR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IKNA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ikena Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
